CEO Bao Presents at the 4th Annual Inner Ear Disorders Therapeutics Summit in Boston, MA

Written By Boran Li

• Developing Disease-Specific Biomarkers to Sub-Type Acquired Hearing Disorders for Improved Therapeutic Interventions

• Identifying specific cochlear damage (i.e. noise-induced and age-related) and the varying scale of synapse damage in sensorineural hearing loss

• Establishing a unified and objective categorization of hearing loss subtypes based on damage to specific cell types, beyond observable changes

• Understanding the lack of translational data following preclinical screening for different noise intensities, noise types, and varying damage in the cochlea

Boran Li
Previous

Hearing Loss in the Unoperated Ear After High-Speed Drilling in Otologic and Skull Base Surgery
Next

COO Brutnell presents at the 4th Annual Inner Ear Disorders Therapeutics Summit in Boston, MA